Auxilium Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Entrepreneurs seeking to fund product-focused businesses during the height of the biotech financing boom faced an uphill battle. "Everybody wanted to invest in rocket science in the middle of 2000," notes Gerri Henwood, president, CEO, and founder of Auxilium Pharmaceuticals Inc. Many VCs questioned Auxilium's mission to develop enhanced products for male hormone replacement therapy (HRT). Despite this initial resistance, Henwood persevered, and her comparatively low-risk company garnered increasing VC attention as it breezed through clinical trials on its first product.
You may also be interested in...
Which Private Investors are Cashing Out?
Every venture capitalist is anxious to use the latest IPO window to get his companies liquid. But some firms are more successful than others. At the top of the list there were few surprises--JP Morgan Partners and Alta Partners, with six biotech IPOs each, and MPM Capital with five. But the next group down contained some newer names.
What Entrepreneurs Want, Get, and Don't Get from VCs
What makes a health care VC stand out in the minds of entrepreneurs? According to a first-of-its-kind survey by Windhover, PricewaterhouseCoopers, Wilson Sonsini, and Applied Information Networks, the answer is value-added services. Entrepreneurs prize VCs who assist them, pre-financing, with constructive feedback and sharing of due diligence results. VCs do pretty well here. But they do less well on the more important post-financing criteria: helping their portfolio companies secure additional financing and recruit customers, partners, and employees.
Cardiokine Inc.
Cardiokine Inc. is one of a new breed of biotechs jumpstarting its pipeline. Its lead program, and the basis for its first round of VC funding, came not from one of its own compounds, but from a compound abandoned by Big Pharma.